TO STUDY THE CARBAPENAM RESISTANT KLEBSIELLA SPECIES AND ITS SUSCEPTIBILITY TOWARDS NOVEL Β- LACTUM / Β LACTAMASE INHIBITOR COMBINATION DRUGS IN PATIENTS ATTENDING A TERTIARY CARE CENTRE
Main Article Content
Keywords
Novel beta-lactam, beta-lactamase, CRKP, BIBLI, Inhibitor, CLSI
Abstract
Introduction: Klebsiella pneumoniae is a Gram-negative organism and a major public health threat. Commercially accessible novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations have been utilised to treat infections caused by Klebsiella pneumoniae (CRKP) that are resistant to carbapenem. To track the development of resistance in these agents, it is essential to continuously analyse susceptibility profiles and identify resistance mechanisms.
Aim And Objective: To Study the carbapenam resistant Klebsiella species and its susceptibility towards novel β- lactum / β lactamase inhibitor combination drugs.
Material And Methods: This was a Cross sectional study carried out in the department of Microbiology for a period of 12 months i.e, October 2021 to October 2022. A total of 300 Klebsiella species from the isolates were tested collected from hospitalized and consultation patients were included in the study. The Antimicrobial susceptibility testing was performed according to the CLSI guidelines.
Results: In the present study a total of 300 Klebsiella species from the isolates were tested out of which Carbapenamses resistant kKbspp was observed to be 204(68%) and Carbapenamses sensitive Kbspp with 96 (32%) with the prevalence rate of 68%. The ratio of females was observed to be more as compared to the males with 64% and 36% respectively. In the present study the maximum number was recorded in the age group of 30-40 (38.7%) years of age followed by 18-30 years with 28.7% and least in and below 18 years with 10%. The maximum isolates were from urine (55%) and least for body fluid with 3%. It was also noted that in the rural area (65.7% ) cases were recorded and urban with 34.3%. In the present study the illiterate were found to be the most with 34.5%, followed by graduates with 23.3 % and least for post graduates with 4.7%. The labour class was the most affected with 34.6%. The Ratio of Male/Female amongst Carbapenamses resistant klebsiella isolates was observed to be 32.9% and 67.1 % respectively. The age group 30-40 was the most commonly affected in Carbapenamses resistant klebsiella isolates with the urine cases most commonly found with 51.4%.
Conclusion: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. Continuous surveillance of susceptibility profiles and resistance mechanism identification are necessary to monitor the evolution of resistance within these agents.
References
2.Xu Z, Li B, Jiang Y, Huang J, Su L, Wu W, Pang Q, Li Z, Zhang J, Li X, Wang J, Cen F, Peng L, Liang J, Wang F, Liu C, Shen C, Liu Y, Yang Y. Development of a quadruple qRT-PCR assay for simultaneous identification of hypervirulent and carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr. 2024 Jan 11; 12(1):e0071923.
3.Revisiting ESKAPE pathogens: virulence, resistance, and combating strategies focusing on quorum sensing. Venkateswaran P, Vasudevan S, David H, Shaktivel A, Shanmugam K, Neelakantan P, Solomon AP. Front Cell Infect Microbiol. 2023; 13:1159798.
4.The characteristic of virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae. Wang G, Zhao G, Chao X, Xie L, Wang H. Int J Environ Res Public Health. 2020; 17.
5.Hypervirulence and multiresistance to antibiotics in Klebsiella pneumoniae strains isolated from patients with hospital- and community-acquired infections in a Mexican medical center. Bautista-Cerón A, Monroy-Pérez E, García-Cortés LR, Rojas-Jiménez EA, Vaca-Paniagua F, Paniagua-Contreras GL. Microorganisms. 2022; 10:2043.
6.Carbapenem-resistant Klebsiella pneumoniae: the role of plasmids in emergence, dissemination, and evolution of a major clinical challenge. Di Pilato V, Pollini S, Miriagou V, Rossolini GM, D'Andrea MM. Expert Rev Anti Infect Ther. 2024; 22:25–43.
7.Diwakar J, Verma RK , Singh DP , Singh A , Kumari S. Phenotypic detection of cabapenem resistance in gram negative bacilli from various clinical specimens of a tertiary care hospital in western Uttar Pradesh Int J Res Med Sci 2017; 3:511-4.
8.Early detection of OXA-232-producing Klebsiella pneumoniae in China predating its global emergence. Heng H, Yang X, Zhang H, et al. Microbiol Res. 2024; 282:127672.
9.Characteristics of non-carbapenemase producing carbapenem-resistant Klebsiella pneumoniae from a tertiary hospital in China. Ruan Y, Li M, Wang D, Duan J, Zhang H, Zhou Y. J Infect Dev Ctries. 2024; 18:106–115.
10.Bacteriological characteristics of hypervirulent Klebsiella pneumoniae rmpA gene (hvKp-rmpA)-harboring strains in the south of Iran. Shoja S, Ansari M, Bengar S, Rafiei A, Shamseddin J, Alizade H. Iran J Microbiol. 2022; 14:475–483.
11.Investigation of virulence genes and carbapenem resistance genes in hypervirulent and classical isolates of Klebsiella pneumoniae isolated from various clinical specimens. Yürek M, Cevahir N. Mikrobiyol Bul. 2023; 57:188–206.
12.Hypervirulent Klebsiella pneumoniae. Russo TA, Marr CM. Clin Microbiol Rev. 2019; 32:1–19.
13.Molecular characterization of Escherichia coli causing urinary tract infections through next-generation sequencing: a comprehensive analysis of serotypes, sequence types, and antimicrobial and virulence genes. Kandi V, Shahapur PR, Suvvari TK, et al. Cureus. 2024; 16:0
14.Best practices for the analytical validation of clinical whole-genome sequencing intended for the diagnosis of germline disease. Marshall CR, Chowdhury S, Taft RJ, et al. NPJ Genom Med. 2020; 5:47
15.A genomic surveillance framework and genotyping tool for Klebsiella pneumoniae and its related species complex. Lam MM, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. Nat Commun. 2021 ;12:4188.
16.Exploring multidrug-resistant Klebsiella pneumoniae antimicrobial resistance mechanisms through whole genome sequencing analysis. Yang J, Zhang K, Ding C, Wang S, Wu W, Liu X. BMC Microbiol. 2023; 23:245
17.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; .
18.Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect. 2014;20(2):156-161.
19.Jennifer H Han et al. Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Network of Long-Term Acute Care Hospitals. Clin Infect Di. 2016 Dec 26;64(7):839–844
20.Kaur Gill M. et al. Antibiogram of Klebsiella pneumoniae isolated from various clinical samples of hospitalized patients in a tertiary care hospital of North India. Tropical Journal of Pathology and Microbiology 2019; 5(8)
21.Biradar S, Roopa C. Isolation and Antibiogram of Klebsiella species from various clinical specimens. Int J Curr Microbiol App Sci. 2015;4(9)991-5. [Crossref][PubMed][Google Scholar]
22.da SilvaSF, ReiI, MonteiroM, et al. Influence of human eating habits on antimicrobial resistance phenomenon: aspects of clinical resistome of gut microbiota in omnivores, ovolactovegetarians, and strict vegetarians. Antibiotics. 202; 10276
23.Sanchita Karet al. High Prevalence of Carbapenem-resistant Klebsiella Pneumoniae in Fecal and Water Samples in Dhaka, Bangladesh. Open Forum Infectious Diseases, Volume 11, Issue 11, November 2024
24.Xing-chen Lin et al. The Global and Regional Prevalence of Hospital-Acquired Carbapenem-Resistant Klebsiella pneumoniae Infection: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases. 2024; Volume 11, Issue 2.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
